Cargando…

Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy

The most prevalent "rare" disease worldwide, cystic fibrosis (CF), is an autosomal recessive multisystem disease, caused by mutations in the CFTR gene. The knowledge of CFTR mutations present in certain population is important for designing a simple, fast and cost-effective genetic testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Terzic, M, Jakimovska, M, Fustik, S, Jakovska, T, Sukarova-Stefanovska, E, Plaseska-Karanfilska, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714339/
https://www.ncbi.nlm.nih.gov/pubmed/31523618
http://dx.doi.org/10.2478/bjmg-2019-0009
_version_ 1783447045706612736
author Terzic, M
Jakimovska, M
Fustik, S
Jakovska, T
Sukarova-Stefanovska, E
Plaseska-Karanfilska, D
author_facet Terzic, M
Jakimovska, M
Fustik, S
Jakovska, T
Sukarova-Stefanovska, E
Plaseska-Karanfilska, D
author_sort Terzic, M
collection PubMed
description The most prevalent "rare" disease worldwide, cystic fibrosis (CF), is an autosomal recessive multisystem disease, caused by mutations in the CFTR gene. The knowledge of CFTR mutations present in certain population is important for designing a simple, fast and cost-effective genetic testing approach, also for better management of CF patients, including the administration of novel targeted therapies. Here, we present genetic results of 158 unrelated CF patients from the National CF Registry of the Republic of North Macedonia. Initially, patients were screened for the 11 most common CF mutations. Additional CF mutations and large deletions/duplications in the CFTR gene were analyzed using commercial kits. If the genotype was undetermined, all CFTR exons were analyzed using Sanger DNA sequencing or next generation sequencing (NGS) (since 2014). The most common CF mutation, c.l521_ 1523del (legacy name F508del), was found with an overall incidence of 75.9%. Additionally, 26 other pathogenic variants and three large deletions were identified in the CFTR gene as a genetic cause of CF. Two of these, c.1070 C>T (p.Ala357Val) and c.2779_2788dup CTTGCTATGG (p.Gly930AlafsTer48), were novel. According to the distribution and prevalence of the pathogenic variants detected in our patients, a fast and cost-effective method, based on a single base extension was designed as a first-line CF genetic test with a 90.0% detection rate within our population. Furthermore, the knowledge of CFTR mutation classes in our CF patients represents the first step toward personalized therapy for CF in our country.
format Online
Article
Text
id pubmed-6714339
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-67143392019-09-13 Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy Terzic, M Jakimovska, M Fustik, S Jakovska, T Sukarova-Stefanovska, E Plaseska-Karanfilska, D Balkan J Med Genet Original Article The most prevalent "rare" disease worldwide, cystic fibrosis (CF), is an autosomal recessive multisystem disease, caused by mutations in the CFTR gene. The knowledge of CFTR mutations present in certain population is important for designing a simple, fast and cost-effective genetic testing approach, also for better management of CF patients, including the administration of novel targeted therapies. Here, we present genetic results of 158 unrelated CF patients from the National CF Registry of the Republic of North Macedonia. Initially, patients were screened for the 11 most common CF mutations. Additional CF mutations and large deletions/duplications in the CFTR gene were analyzed using commercial kits. If the genotype was undetermined, all CFTR exons were analyzed using Sanger DNA sequencing or next generation sequencing (NGS) (since 2014). The most common CF mutation, c.l521_ 1523del (legacy name F508del), was found with an overall incidence of 75.9%. Additionally, 26 other pathogenic variants and three large deletions were identified in the CFTR gene as a genetic cause of CF. Two of these, c.1070 C>T (p.Ala357Val) and c.2779_2788dup CTTGCTATGG (p.Gly930AlafsTer48), were novel. According to the distribution and prevalence of the pathogenic variants detected in our patients, a fast and cost-effective method, based on a single base extension was designed as a first-line CF genetic test with a 90.0% detection rate within our population. Furthermore, the knowledge of CFTR mutation classes in our CF patients represents the first step toward personalized therapy for CF in our country. Sciendo 2019-08-28 /pmc/articles/PMC6714339/ /pubmed/31523618 http://dx.doi.org/10.2478/bjmg-2019-0009 Text en © 2019 Terzic M, Jakimovska M, Fustik S, Jakovska T, Sukarova-Stefanovska E, Plaseska-Karanfilska D, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Article
Terzic, M
Jakimovska, M
Fustik, S
Jakovska, T
Sukarova-Stefanovska, E
Plaseska-Karanfilska, D
Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title_full Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title_fullStr Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title_full_unstemmed Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title_short Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy
title_sort cystic fibrosis mutation spectrum in north macedonia: a step toward personalized therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714339/
https://www.ncbi.nlm.nih.gov/pubmed/31523618
http://dx.doi.org/10.2478/bjmg-2019-0009
work_keys_str_mv AT terzicm cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy
AT jakimovskam cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy
AT fustiks cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy
AT jakovskat cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy
AT sukarovastefanovskae cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy
AT plaseskakaranfilskad cysticfibrosismutationspectruminnorthmacedoniaasteptowardpersonalizedtherapy